Intercept’s NASH Drug Delayed By April Advisory Committee, But Firm Is Ready For Launch

 
• By Joseph Haas

Intercept announced that the US FDA has set April 22 as date for an advisory committee review of OCA in NASH, meaning March 26 action date could be pushed back as much as three months.

liver
An FDA advisory committee for OCA was expected, but scheduling it after the PDUFA date was a surprise

More from New Products

More from Scrip